Micaela M ViÑa-Romero1, Ruth Ramos-Diaz2, Ivette Mourani-Padron2, Hector Gonzalez-Mendez3, Macarena Gonzalez-Cruz4, Gloria Julia Nazco-Casariego5, Javier F Merino-Alonso1, Jesica Diaz-Vera2, Fernando GutiÉrrez-NicolÁs6. 1. Hospital Pharmacy Service, University Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Tenerife, Spain. 2. Foundation of Health Research Institute of Canary islands (FIISC), University Hospital of the Canary islands, La Laguna, Tenerife, Spain. 3. Hematology Service, University Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Tenerife, Spain. 4. Paediatric Service, University Hospital of the Canary islands, La Laguna, Tenerife, Spain. 5. Hospital Pharmacy Service, University Hospital of the Canary islands, La Laguna, Tenerife, Spain. 6. Hospital Pharmacy Service, University Hospital of the Canary islands, La Laguna, Tenerife, Spain fgunico@gmail.com.
Abstract
BACKGROUND/AIM: L-Asparaginase (L-ASNase) is used as a tumor-inhibitory drug on paediatric acute lymphoblastic leukemia (ALL). ERW-ASNase is commercialised as a lyophilized powder stable only for 8 hours once reconstituted and, consequently, the leftover is usually discarded. The aim of this study will be to analyse the stability of the reconstituted lyophilised ERW-ASNase. MATERIALS AND METHODS: In the present study, we analysed the enzymatic stability of reconstituted ERW-ASNase after conservation in three different temperature conditions for 2 and 5 days. RESULTS: Our results show that ERW-ASNase is stable at 4°C, -20°C and -80°C for up to 5 days, retaining 95% of the initial enzymatic activity in all three storage temperatures tested. CONCLUSION: It is feasible to reuse the remaining content of ERW-ASNase vial after reconstitution, which allows the optimization of the content of ERW-ASNase vials use and reduces the cost of this formulation usage, making it more accessible. Copyright
BACKGROUND/AIM: L-Asparaginase (L-ASNase) is used as a tumor-inhibitory drug on paediatric acute lymphoblastic leukemia (ALL). ERW-ASNase is commercialised as a lyophilized powder stable only for 8 hours once reconstituted and, consequently, the leftover is usually discarded. The aim of this study will be to analyse the stability of the reconstituted lyophilised ERW-ASNase. MATERIALS AND METHODS: In the present study, we analysed the enzymatic stability of reconstituted ERW-ASNase after conservation in three different temperature conditions for 2 and 5 days. RESULTS: Our results show that ERW-ASNase is stable at 4°C, -20°C and -80°C for up to 5 days, retaining 95% of the initial enzymatic activity in all three storage temperatures tested. CONCLUSION: It is feasible to reuse the remaining content of ERW-ASNase vial after reconstitution, which allows the optimization of the content of ERW-ASNase vials use and reduces the cost of this formulation usage, making it more accessible. Copyright
Authors: Wing H Tong; Rob Pieters; Gertjan J L Kaspers; D Maroeska W M te Loo; Marc B Bierings; Cor van den Bos; Wouter J W Kollen; Wim C J Hop; Claudia Lanvers-Kaminsky; Mary V Relling; Wim J E Tissing; Inge M van der Sluis Journal: Blood Date: 2014-01-21 Impact factor: 22.113
Authors: L B Silverman; R D Gelber; V K Dalton; B L Asselin; R D Barr; L A Clavell; C A Hurwitz; A Moghrabi; Y Samson; M A Schorin; S Arkin; L Declerck; H J Cohen; S E Sallan Journal: Blood Date: 2001-03-01 Impact factor: 22.113
Authors: Claudia Lanvers-Kaminsky; Andrea Rüffer; Gudrun Würthwein; Joachim Gerss; Massimo Zucchetti; Andrea Ballerini; Andishe Attarbaschi; Petr Smisek; Christa Nath; Samiuela Lee; Sara Elitzur; Martin Zimmermann; Anja Möricke; Martin Schrappe; Carmelo Rizzari; Joachim Boos Journal: Ther Drug Monit Date: 2018-02 Impact factor: 3.681
Authors: J B Nachman; H N Sather; M G Sensel; M E Trigg; J M Cherlow; J N Lukens; L Wolff; F M Uckun; P S Gaynon Journal: N Engl J Med Date: 1998-06-04 Impact factor: 91.245
Authors: L A Clavell; R D Gelber; H J Cohen; S Hitchcock-Bryan; J R Cassady; N J Tarbell; S R Blattner; R Tantravahi; P Leavitt; S E Sallan Journal: N Engl J Med Date: 1986-09-11 Impact factor: 91.245
Authors: Joyson J Karakunnel; Nam Bui; Latha Palaniappan; Keith T Schmidt; Kenneth W Mahaffey; Briggs Morrison; William D Figg; Shivaani Kummar Journal: J Transl Med Date: 2018-12-04 Impact factor: 5.531